Pharma News Intelligence April 5, 2024
AllianceRx Walgreens gains exclusive access to VIVJOA, the first FDA-approved post-menopausal medication for reducing recurrent vulvovaginal candidiasis (RVVC).
In a move set to revolutionize treatment options for post-menopausal women and those not of reproductive potential, Walgreens specialty pharmacy patients now have exclusive access to VIVJOA, an antifungal medication manufactured by Mycovia Pharmaceuticals. VIVJOA (oteseconazole) is the first FDA-approved medication designed to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in this demographic by inhibiting fungal growth.
RVVC is a condition characterized by repeated episodes of vaginal yeast infections caused by the fungus Candida. It profoundly affects patients’ comfort and quality of life, manifesting in symptoms such as itching, burning, irritation, and abnormal vaginal discharge.
Walgreens specialty pharmacy patients now have...
Today's Sponsors
Today's Sponsor